Clinical trial
99Tc-MDP Versus Celecoxib Treatment in Patients With Knee Osteoarthritis
Name
osteoarthritis
Description
Osteoarthritis (OA) of knee is the most common form of arthritis in the world1e, and it has received growing attention in the society because of the increase of old age population, disabled people, and medical expenses from this disease. 99Tc-MDP is effective for rheumatoid arthritis. Therefore, the investigators try to investigate the effects of 99Tc-MDP treatment in patients with osteoarthritis of knee as compared with celecoxib.
Trial arms
Trial start
2017-09-01
Estimated PCD
2024-12-30
Trial end
2024-12-30
Status
Recruiting
Treatment
99Tc-MDP
99Tc-MDP 15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.
Arms:
99Tc-MDP
Other names:
Yunke
Celecoxib
Celecoxib capsule 200mg qd by mouth.
Arms:
celecoxib
Other names:
Xile Bao
Size
40
Primary endpoint
pain, stiffness and joint function of knee
baseline, and 6, 12 months after treatment.
Eligibility criteria
Inclusion Criteria:
1. Participants with painful osteoarthritis;
2. The standard uptake value (SUV) of OA related knee greater than 10 on 18F- sodium fluoride bone scan;
3. Participants voluntarily participate in the trial, and signed the informed consent.
Exclusion Criteria:
1. Knee joint replacement;
2. Inflammatory arthritis or joint infection of knee;
3. Nervous joint disease;
4. Fracture of joint;
5. Gout arthritis of the knee;
6. Traumatic arthritis.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}
Updated at
2023-11-22
1 organization
1 product
1 drug
1 indication
Product
99Tc-MDPIndication
Treatment OutcomeDrug
Celecoxib